tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OCUL Stock Latest News

Ocular Therapeutix price target raised to $27 from $24 at BofA
The FlyOcular Therapeutix price target raised to $27 from $24 at BofA
7d ago
OCUL
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
PremiumRatings
OCUL: SOL-1 Phase 3 Data, Regulatory Strategy, and Durability Advantages Underpin Reaffirmed Buy Rating and $27 Target
7d ago
OCUL
Ocular Therapeutix price target raised to $28 from $21 at Clear Street
PremiumThe Fly
Ocular Therapeutix price target raised to $28 from $21 at Clear Street
7d ago
OCUL
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
PremiumRatings
Axpaxli’s Superior SOL-1 Phase 3 Data Support Buy Rating and Constructive Outlook on Ocular Therapeutix
7d ago
OCUL
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
PremiumRatings
OCUL: Strengthening Axpaxli Clinical Profile and Manageable Safety Support Buy Rating in Neovascular AMD
7d ago
OCUL
Ocular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress
PremiumCompany AnnouncementsOcular Therapeutix Highlights Phase 3 AXPAXLI Trial Progress
10d ago
8K
OCUL
Ocular Therapeutix selloff brings attractive entry point, says Citizens
Premium
The Fly
Ocular Therapeutix selloff brings attractive entry point, says Citizens
20d ago
OCUL
Midday Fly By: Warner Bros. reopens Paramount talks
Premium
The Fly
Midday Fly By: Warner Bros. reopens Paramount talks
20d ago
DG
DHR
Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating
PremiumRatings
Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating
20d ago
OCUL
Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff
PremiumThe Fly
Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff
20d ago
OCUL
Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint
PremiumThe Fly
Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint
21d ago
OCUL
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks
PremiumCompany Announcements
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks
1M ago
OCUL
Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)
PremiumThe FlyOcular Therapeutix reports Q4 EPS (29c), consensus (34c)
1M ago
OCUL
Ocular Therapeutix appoints Jason Robins interim CFO
Premium
Company Announcements
Ocular Therapeutix appoints Jason Robins interim CFO
2M ago
8K
OCUL
Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer
Premium
The Fly
Ocular Therapeutix appoints Robinson as Global Chief Commercial Officer
2M ago
MRK
OCUL
Unusually active option classes on open January 16th
PremiumThe Fly
Unusually active option classes on open January 16th
2M ago
LAC
LDI
Sanofi prepping higher bid for Ocular Therapeutix, IBD reports
PremiumThe Fly
Sanofi prepping higher bid for Ocular Therapeutix, IBD reports
2M ago
SNY
OCUL
Ocular Therapeutix rises 11.7%
PremiumThe Fly
Ocular Therapeutix rises 11.7%
2M ago
OCUL
Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
PremiumCompany Announcements
Ocular Therapeutix Enters Quiet Period Ahead of SOL-1 Milestone
3M ago
8K
OCUL
Strong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
PremiumRatingsStrong Buy Rating for Ocular Therapeutix Backed by Enhanced Regulatory Pathway and Promising Axpaxli Trial Data
3M ago
OCUL
Ocular Therapeutix price target raised to $21 from $18 at BofA
Premium
The Fly
Ocular Therapeutix price target raised to $21 from $18 at BofA
3M ago
OCUL
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
Premium
The Fly
Mizuho remains bullish on EyePoint as competitor makes move for ‘Pole Position’
3M ago
EYPT
OCUL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >